| Basics |
iBio, Inc.
iBio Inc is a biotechnology company. It is engaged in commercializing its proprietary platform technologies, iBioLaunch for vaccines and therapeutic proteins & iBioModulator for vaccine enhancement and developing select product candidates.
|
| IPO Date: |
January 4, 2011 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$16.41M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.08 | 5.67%
|
| Avg Daily Range (30 D): |
$0.03 | 4.47%
|
| Avg Daily Range (90 D): |
$0.04 | 4.79%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.7M |
| Avg Daily Volume (30 D): |
1.26M |
| Avg Daily Volume (90 D): |
1.77M |
| Trade Size |
| Avg Trade Size (Sh.): |
516 |
| Avg Trade Size (Sh.) (30 D): |
347 |
| Avg Trade Size (Sh.) (90 D): |
310 |
| Institutional Trades |
| Total Inst.Trades: |
120 |
| Avg Inst. Trade: |
$1.48M |
| Avg Inst. Trade (30 D): |
$1.08M |
| Avg Inst. Trade (90 D): |
$1.08M |
| Avg Inst. Trade Volume: |
M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.78M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
4.78K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-1.75
|
$-.31
|
$-1.75
|
|
Diluted EPS
|
$-1.75
|
$-.31
|
$-1.75
|
|
Revenue
|
$ .4M
|
$ .2M
|
$ .4M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -18.38M
|
$ -5.16M
|
$ -18.38M
|
|
Operating Income / Loss
|
$ -18.6M
|
$ -5.2M
|
$ -18.6M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -5.63M
|
$ 3.61M
|
$ -5.63M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 29, 2023:
1:20
|
|
Oct 10, 2022:
1:25
|
|
Jun 11, 2018:
1:10
|
|
|
|
